Abstract:Background: Rank preserving structural failure time (RPSFT) is a statistical method to correct or adjust for crossover in clinical trials, by estimating the counterfactual effect on overall survival (OS) when control arm patients do not receive the interventional drug when their tumor progresses. We sought to examine the strength of correlation between differences in uncorrected and corrected OS hazard ratios and percentage of crossover, and characterize instances of fundamental and sequential efficacy. Methods: In a cross-sectional analysis (2003-2023), we reviewed oncology randomized trials that used RPSFT analysis to adjust the OS hazard ratio for patients who crossed over to an anti-cancer drug. We calculated the percentage of RPSFT studies evaluating a drug for fundamental efficacy (with or without a standard of care (SOC)) or sequential efficacy and the correlation between the OS hazard ratio difference (unadjusted and adjusted) and the percentage of crossover. Results: Among 65 studies, the median difference between the uncorrected and corrected OS hazard ratio was -0.1 (quartile 1, quartile 3 : -0.3 to -0.06). The median percentage of crossover was 56% (quartile 1, quartile 3: 37% to 72%). All studies were funded by the industry or had authors who were employees of the industry. Twelve studies (19%) tested a drug's fundamental efficacy when there was no SOC; 34 studies (52%) tested a drug's fundamental efficacy when there was already a SOC; and 19 studies (29%) tested a drug's sequential efficacy. The correlation between the uncorrected and corrected OS hazard ratio difference and the percentage of crossover was 0.44 (95% CI: 0.21 to 0.63). Conclusions: RPSFT is a common tactic used by the industry to reinterpret trial results. Nineteen percent of RPSFT use is appropriate. We recognize that while crossover can bias OS results, the allowance and handling of crossover in trials should be limited to appropriate circumstances.

Correcting for Non-compliance in Randomized Trials Using Rank Preserving Structural Failure Time Models

Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use

Assessing contribution of treatment phases through tipping point analyses using rank preserving structural failure time models

Response adaptive randomization procedures in seamless phase II/III clinical trials.

Multiple random change points in survival analysis with applications to clinical trials

Testing Hypotheses of Covariate-Adaptive Randomized Clinical Trials with Time-to-event Outcomes under the AFT Model

Assessing contribution of treatment phases through tipping point analyses via counterfactual elicitation using rank preserving structural failure time models

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Supplementary Figure S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Supplementary Table S3 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Effect of difference censored rates between groups in clinical trails

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data

Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials

Estimating the Causal Effects in Randomized Trials for Survival Data with A Cure Fraction and Non Compliance

Nonparametric analysis of delayed treatment effects using single‐crossing constraints

Adaptive Randomization for Clinical Trials with Delayed Response

Accelerated failure time models with error-prone response and nonlinear covariates

Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation due to adverse events

Simulation Study of Multi-Stage Randomized-Play-the-winner-rule

Estimating treatment effect in randomized trial after control to treatment crossover using external controls